Latest Biotech News

Page 22 of 27
Noxopharm Limited has raised nearly $2.5 million by selling its entire stake in Nyrada Inc, providing non-dilutive capital to advance its HERACLES clinical trial and expand its research pipeline.
Ada Torres
Ada Torres
20 May 2025
ITM Isotope Technologies Munich SE and Radiopharm Theranostics have entered a strategic supply agreement for the critical radioisotope Lutetium-177, underpinning Radiopharm’s clinical development of targeted cancer therapies.
Ada Torres
Ada Torres
19 May 2025
Neuren Pharmaceuticals has received official FDA minutes confirming the primary endpoints for its pivotal Phase 3 trial of NNZ-2591 targeting Phelan-McDermid syndrome, reinforcing the positive signals from earlier studies.
Ada Torres
Ada Torres
13 May 2025
AdAlta Limited has announced a pro rata renounceable rights offer to raise approximately $1.29 million, aiming to fund its strategic pivot towards licensing CAR-T cell therapies through its subsidiary AdCella. The offer includes new shares and options, underpinned by key insiders and an underwriting agreement.
Ada Torres
Ada Torres
5 May 2025
Alterity Therapeutics has secured FDA Fast Track designation for ATH434, its lead candidate for treating Multiple System Atrophy, potentially speeding up regulatory review and bringing hope to patients with this rare neurodegenerative disorder.
Ada Torres
Ada Torres
5 May 2025
Nyrada Inc. has cleared the Safety Review Committee’s scrutiny for its Phase I clinical trial, progressing to the third dosing cohort of its promising neuroprotective and cardioprotective drug candidate NYR-BI03.
Ada Torres
Ada Torres
2 May 2025
Anagenics Limited reported a cash outflow of $424K for Q3 2025 but maintains robust liquidity with $1.48 million in available funding, supported by a mix of secured and unsecured loans.
Ada Torres
Ada Torres
1 May 2025
BluGlass Limited has achieved a world-record 1250mW single-mode GaN laser chip and strengthened its commercial pipeline with a $120,000 repeat order, positioning itself for rapid growth in photonics markets.
Sophie Babbage
Sophie Babbage
30 Apr 2025
Hexima Limited reported a stable cash position of $1.55 million at quarter-end, with a modest $87,000 net cash outflow from operations. The biotech company continues to explore strategic opportunities while maintaining a strong funding runway.
Ada Torres
Ada Torres
30 Apr 2025
EVE Health Group has executed a binding agreement to acquire Australian biotech Nextract, targeting rapid-onset treatments in the $16 billion global erectile dysfunction and dysmenorrhea markets. The acquisition, supported by a $1.5 million capital raise and share consolidation, marks a strategic shift into regulated pharmaceutical channels.
Ada Torres
Ada Torres
30 Apr 2025
Imagion Biosystems has progressed its MagSense HER2 breast cancer imaging agent towards a pivotal Investigational New Drug application with the FDA, backed by a solid funding runway exceeding 13 quarters.
Ada Torres
Ada Torres
30 Apr 2025
Tissue Repair Limited reports progress in its Phase 3 clinical trials for TR987® despite enrollment delays caused by US regulatory disruptions, while TR Pro+® sales hit record highs and manufacturing scale-up advances.
Ada Torres
Ada Torres
30 Apr 2025